Dr. McKay on FDA Approval of Frontline Cabozantinib in RCC

Rana R. McKay, MD

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of cabozantinib (Cabometyx) in the frontline setting for patients with renal cell carcinoma (RCC).
Printer Printing...